Desmopressin

Desmopressin (1-deamino-8-D-arginine vasopressin) is produced by two structural modifications to native arginine vasopressin: deamination of the N-terminal cysteine residue and substitution of L-arginine at position 8 with D-arginine. These changes confer prolonged duration of action and highly selective agonism at the vasopressin V2 receptor while eliminating most vasopressor activity. The antidiuretic-to-pressor potency ratio is approximately 2,000–4,000:1, compared with 1:1 for native vasopressin.

• Renal antidiuresis: V2 receptors on the principal cells of the distal convoluted tubule and collecting duct are Gs-protein-coupled receptors. Desmopressin binding activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and triggers phosphorylation-dependent trafficking and apical membrane insertion of aquaporin-2 (AQP2) water channels. This markedly increases collecting duct water permeability, concentrates urine, and reduces urine volume without significant activation of V1a receptors responsible for vasoconstriction.

• Hemostasis: V2 receptors on vascular endothelial cells mediate cAMP-dependent exocytosis of Weibel-Palade bodies, releasing stored von Willebrand factor (VWF) and tissue-type plasminogen activator into circulation. A standard 0.3 mcg/kg intravenous dose raises plasma VWF and factor VIII (FVIII) two- to five-fold within 30–60 minutes. Because desmopressin mobilizes pre-formed endothelial stores rather than stimulating new protein synthesis, repeated dosing at short intervals depletes those stores and produces tachyphylaxis.

Central diabetes insipidus (CDI): Desmopressin has been the first-line pharmacological treatment for CDI since its clinical introduction in the late 1970s. Large randomized controlled trials are limited by disease rarity, but extensive pharmacokinetic, observational, and endocrinological data confirm reliable reduction in urine volume and restoration of normal urine osmolality across all etiologies of CDI, including post-surgical and post-traumatic polyuria.

Bleeding disorders: A 2025 systematic review (PMC12292229) analyzed pooled data from multiple cohorts including 229 patients with von Willebrand disease (VWD). Complete biological response — defined as VWF:RCo and FVIII activity both rising above 50 U/dL — was achieved in 89% of patients; 10% showed partial response and 1% did not respond. A retrospective series of 94 VWD cases reported an 89.4% response rate. Response rates vary substantially by VWF genotype: patients without identifiable mutations achieved 100% response, those with D-D3 domain mutations 64.3%, and those with A1-A3 domain mutations 31.3%. In hemophilia A, response rates range from approximately 90% in hemophilia A carriers to 54% in mild disease and 16% in moderate disease. The FDA prescribing information states that a 0.3 mcg/kg IV dose produces a 300–400% change in FVIII from baseline, with peak at 90 minutes to 2 hours post-infusion.

Nocturnal enuresis: A 2002 Cochrane systematic review (PMID 12137645) of 41 randomized controlled trials enrolling 2,760 children (1,813 receiving desmopressin) found desmopressin consistently reduced wet nights per week versus placebo across multiple doses and formulations. A 2023 meta-analysis (PMC10620680; 8 RCTs, 600 patients) showed that adding an anticholinergic agent produced superior full-response rates versus desmopressin alone: OR 3.18 (95% CI 1.91–5.28; P less than 0.00001) at three months, without significant increase in adverse events.

Nocturia: Clinical trials supporting Nocdurna's FDA approval demonstrated a 52% mean reduction in nocturnal voids in women and 43% in men; 78% of women and 67% of men achieved at least a 33% reduction in nocturnal void frequency over three months versus baseline.

Typical dosage: 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) (Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia)).

Parenteral (DDAVP injection, 4 mcg/mL): • Central diabetes insipidus: 2 to 4 mcg per day by subcutaneous or intravenous injection in one or two divided doses, adjusted individually to the minimum effective dose based on urine volume and osmolality response. • Hemophilia A and Type I von Willebrand disease: 0.3 mcg/kg (maximum 20 mcg) by intravenous infusion over 15 to 30 minutes, approximately 30 minutes before a surgical procedure or at the time of bleeding. Repeat doses may be given every 8 to 12 hours; dosing more frequently than every 48 hours carries risk of tachyphylaxis.

Oral tablets (DDAVP 0.1 mg, 0.2 mg): • Central diabetes insipidus: start 0.05 mg twice daily; titrate to an optimal range of 0.1 to 0.8 mg/day in divided doses; maximum 1.2 mg/day in two to three divided doses. • Primary nocturnal enuresis (age 6 and older): 0.2 mg at bedtime; may increase up to 0.6 mg if needed.

Intranasal high-concentration spray (Stimate, 1.5 mg/mL): • Hemophilia A and Type I VWD: one 150 mcg spray per nostril (300 mcg total) for patients weighing at least 50 kg; one spray (150 mcg) in one nostril for patients under 50 kg, administered approximately 2 hours before a procedure.

Sublingual tablets (Nocdurna): • Nocturia due to nocturnal polyuria: 27.7 mcg (males) or 55.3 mcg (females) once nightly, at least one hour before bedtime. Serum sodium must be normal before starting therapy and is contraindicated when CrCl is below 50 mL/min.

Fluid restriction from one hour before to eight hours after each dose is required across all indications to reduce the risk of hyponatremia. Serum sodium must be measured within one week of initiating treatment and approximately one month later.

This information is for educational purposes only and does not constitute medical advice. Dosing decisions must be individualized and supervised by a licensed healthcare provider with full knowledge of the patient's medical history, concurrent medications, and renal function.

In mild hemophilia A and Type I von Willebrand disease, desmopressin is frequently co-administered with antifibrinolytic agents — most commonly tranexamic acid or epsilon-aminocaproic acid — to stabilize fibrin clots after peak VWF and factor VIII release. This strategy is standard practice for minor surgical procedures and dental extractions; the antifibrinolytic is often continued orally for several days following a single perioperative DDAVP infusion.

For primary nocturnal enuresis, a 2023 meta-analysis (8 RCTs, 600 patients; PMC10620680) found that combining desmopressin with an anticholinergic agent (principally oxybutynin) produced significantly superior full-response rates versus desmopressin monotherapy at three months (OR 3.18; 95% CI 1.91–5.28; P less than 0.00001), without a statistically significant increase in adverse events.

Loop diuretics and systemic or inhaled glucocorticoids are contraindicated in combination with desmopressin due to markedly increased risk of hyponatremia. Medications independently associated with hyponatremia — including SSRIs, tricyclic antidepressants, NSAIDs, thiazide diuretics, carbamazepine, opioids, and chlorpropamide — require more frequent serum sodium monitoring when co-prescribed with desmopressin.

Desmopressin is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: hyponatremia (boxed warning), headache, facial flushing, nausea, abdominal cramps, fluid retention, hypotension, reflex tachycardia, hypertension, tachyphylaxis with repeated dosing, rare anaphylaxis

Boxed warning — Hyponatremia: Desmopressin can cause severe, potentially life-threatening hyponatremia. Sequelae include seizures, coma, respiratory arrest, and death. Serum sodium must be confirmed normal before initiating or resuming therapy and must be measured within one week and approximately one month after starting; patients aged 65 years and older and those with additional risk factors require more frequent monitoring. Fluid intake should be restricted from one hour before to eight hours after each dose.

Common adverse reactions include headache (approximately 4% in nocturnal enuresis clinical trials versus 3% placebo), facial flushing, nausea, abdominal cramps, and fluid retention. Intravenous administration may cause transient hypertension or hypotension with reflex tachycardia; blood pressure should be monitored during infusion, particularly in patients with coronary artery insufficiency or hypertensive cardiovascular disease.

Rare but serious reactions include hypersensitivity responses up to and including anaphylaxis; fatal cases have been reported with intravenous DDAVP. The drug must be permanently discontinued for serious hypersensitivity reactions.

Tachyphylaxis is a recognized clinical phenomenon when dosing occurs more frequently than every 48 hours; endothelial factor stores are depleted and responsiveness typically returns after a 2- to 3-day rest interval.

Desmopressin is contraindicated in: known hypersensitivity to the compound; moderate-to-severe renal impairment (CrCl below 50 mL/min); current or prior hyponatremia; SIADH; polydipsia; heart failure; uncontrolled hypertension; and concurrent use of loop diuretics or systemic or inhaled glucocorticoids. In Type IIB von Willebrand disease, desmopressin can trigger platelet aggregation and thrombocytopenia and is generally contraindicated. Type III VWD and hemophilia A with FVIII below 1 U/dL are not expected to respond and are not approved indications.